Evaluation of Typical Antipsychotic Augmentation with Citalopram in Reduction of Negative Symptoms in Inpatient Schizophrenia in Ahvaz Golestan Hospital

Document Type : Original Article

Authors

1 Assistant Professor of Psychiarty. Department of Psychiatry, School of Medicine , Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

2 Assistant Professor of Psychiatry.Department of Psychiatry, School of Medicine , Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

3 Assistant Professor of Psychiatry. Department of Psychiatry, School of Medicine , Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Abstract

Background and Objective: The aim of this study was to
 evaluate the efficacy of citalopram added to   typical antipsychotic  for the treatment of negative symptoms  of inpatients with schizophrenia disorder  in Ahvaz Golestan hospital.
Subjects and Methods: Forty inpatients suffering fromschizophrenia disorder (DSM-IV-TR) were recruited for a randomized double blind clinical trial. Depression was ruled out by Hamilton Depression Questionnaire. They were randomly assigned to either citalopram (20 mg for first week and 40 mg for next weeks) or placebo added on while the typical antipsychotic was continued. The efficacy of drugs was assessed weekly with PANSS scale during 6 weeks. 
Results: Mean age was 37/22 years and 60% (n=24) were male. Citalopram did not improve negative symptoms in schizophrenia patients compared to placebo. Citalopram improved   general psychopathology symptoms and total PANSS.
Conclusion: Citalopram improved   general psychopathology symptoms and total PANSS. Adding citalopram on typical antipsychotic treatment did not improve negative symptoms in patients with schizophrenia disorder. 

Keywords

References

1-Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock's comprehensive textbook of psychiatry. 9th ed. Philadelphia : Wolters Kluwer/Lippincott Williams & Wilkins; 2009. P. 1432-556.
2-Sadock  BG , Sadock VA. Kaplan & Sadock's synopsis of psychiatry: behavioral science/clinical psychiatry. 10th ed. Philadelphia: Lippincott, Williams & Wilkins; 2007.
3-Shoja-Shafti S. [EffectIveness of Bromocriptine, Flouxetine and Nortriptyline in reduction  of Negative Symptoms of Schizophrania]. J Rehabilitation 2004;5(1):10 -7. [Article in Persian]                                                                                                                                                                                                                                                                                                                                                                                
4-Shoja-Shafti S. [Effectiveness of citalopram alprazolam, clomipramine in amelioration of negative symptoms in schizopherenia]. J Rehabilitation 2003;3(12):42-9. [Article in Persian]                                                                        
5-Melle I, Johannesen J friis S, Haahr U, Joa I, Larsen TK, et al. Early detection of the first episode of schizophrenia and suicidal behavior. Am J Psychiatry 2006;163(5):800-4.
6-Gelder MG, Harrison PJ, Cowen Ph. Shorter oxford Textbook of Psychiatry. 5th ed. Oxford: Oxford University Press; 2006. P. 267-306.
7-Silver H. Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug  Reviews;7(3):283-304.
8-Erhart SM, Marder SR, Carpenter WT. Treatment of Schizophrenia Negative Symptoms: Future Prospects. Schizophr Bull 2006;32(2):234-7.
9-Shoja-Shafti S, Bakhtiari M. [Evaluation of prevalance of negetive symptoms in1% inpationts Schizophrenic ]. J Rehabilitation 2003;:38-47. [Article in Persian]                                                                       
 10-Siris SG, Mason SE, Bermanzohn PC, Alvir JM. Adjunctive imipramine maintenance in post-psychotic depression/negative symptoms. Psychopharmacology Bull1990;26(1):91-4. 
11-Raedler TJ, Jahn H, Arlt J, Kiefer F, Schick M, Naber D, et al. Adjunctive use of reboxetine in schizophrenia. Europian Psychiatry 2004;19:366-9.
12-Salokangas RKR, Saarijarvi S, Taiminen T, Kallioniemi H, Lehto H, Niemi H, et al. Citalopram as an adjuvant in chronic schizophrenia:a double-blind placebo-controlled study.Acta Psychiatrica Scandinavica 1996;94(3):175-80.
13-Salokangas RKR, Taiminen T. Citalopram as an adjuvant in   schizophrenia:Furthur evidence for a serotonergic dimension in schizophrenia. Int Clin psychopharmacolo1997;12:31-5. (
14- Goff DC, Amico E, Sarid-Segal O,  Midha KK, Hubbard JW. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology 1995;117(4):417-23.
15-SardarpurSh, Arbabi M. Efficacy of naltroxan in treatment of  schizophrenia. A double- blind, placebo-controlled clinical trial. Iran clin Psychiatry J 2006;12:49-54. [Article in Persian](
16-Phayezi B. [Efficacy of selgilin in schizophrenia negative symptoms]. A double- blind study. Iran clin Psychiatry 2008; :131-9. [Article in Persian]
17-Maleki M, Javidi Z, Kiafar B, Saadatian V, Saremi AK. [Depression in vitiligo patients]. The Quarterly Journal of Fundamentals of Mental Health 2005;(25-26):5-11. [Article in Persian]
18-Sepehri AA. SSRI ass-on therapy for the negative symptoms of schizophrenia: a meta- analysis. J Clin psychiatry 2007;68(4):604-10.
19-Takahashi H, Sugita T, Higuchi H, Shimizu T. Fluvoxamine augmentation in risperidone- resistant schizophrenia: an open trial. Hum psychooharmacol: Clin & Exp 2002;17:95-8.
20-Nasre esfahani  M, HamidiA. Effects of bromocriptin on Negative Symptoms of Schizophrenia: A Double Blind Clinical Trial. Iranian Journal of Pharmacology and Therapeutics 2001;1(1):175-81.
21-Inacu I, Tschernihovsky E, Bodner E, Piconne AS, Lowengrub K.Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: A randomized double – blind placebo-controlled trial. Psychiatry Res 2010;179(1):19-23.
22-Taiminen TJ, Syvalahti E, Saarijärvi S, Niemi H, Lehto H, Ahola V, et al. Citalopram as an adjuvant in schizophrenia: further evidence for a serotonergic dimension in schizophrenia. Int ClinPsychopharmacol 1997;12(1):31-5.
23-Shoja-Shafti S. Treatment– Responsiveness of negative symptoms in schizophrenia: A double- blind placebo-control clinical trial. Iran J Med Sci 2006;31(3):135-8.
24-Shoja-Shafti S. Amelioration f negatvie symptoms in schizophrenia by escitalopram: A double- blind, placebo-controlled clinical trial. Clinical schizophrenia & related psychoses 2007;1(3):255-8.
25-Avenoso A, Facciolà G, Scordo MG, Gitto C, Ferrante GD, Madia AG, et al. No Effect of citalopram on plasma levels of clozapine, risperidone and their active metabolites in patients with chronic schizophrenia.Clin drug Investigation  1998;16(5):393-8.
26-Kasckow JW, Mohamed S, Thallasinos A, Carroll B, Zisook S, Jeste DV. Citalopram augmentation of antipsychotic treatment in older schizophrenia patients. Int J Geriatr Psychiatry 2001;16(12):1163-7.
27-Silver H. Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert Opin Pharmacother 2004;5(10):2053-8.
28-Singh SP, Singh V, Kar N, Chan K. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta- analysis.Br JPsychiatry 2010;197(3):174-9.
Jundishapur Scientific Medical Journal
Volume 11, Issue 4 - Serial Number 79
July and August 2017
Pages 439-448

Files

History

  • Receive Date: 27 September 2011
  • Revise Date: 28 November 2011
  • Accept Date: 27 February 2012

Share

How to cite

Statistics